LTR Pharma Extends SPONTAN Shelf Life to 18 Months, Strengthening Commercial Potential

LTR Pharma Limited (ASX: LTP) announced a major milestone for its lead product, SPONTAN®, which has achieved an 18-month shelf life under international ICH stability standards. This extension surpasses current distribution requirements and enhances the product’s readiness for global commercialization in the erectile dysfunction (ED) market, projected to reach US$6 billion by 2028. The result validates the robustness of SPONTAN’s formulation, delivery system, and packaging, while reinforcing the company’s manufacturing and distribution capabilities across Australia.

Importantly, the extended stability strengthens SPONTAN’s regulatory submissions in the US, Europe, and Asia, positioning it competitively against oral PDE5 inhibitors such as Viagra and Cialis, while maintaining its key advantage of a rapid 10-minute onset. LTR Pharma is continuing its stability program through 24 months, potentially enabling further extensions and creating commercial flexibility. Management views this as a pivotal step toward expanding global access.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com